Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis

NCT01982942 is registered in ClinicalTrials.gov with MediciNova as lead sponsor.

NCT NCT01982942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01982942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis
Lead sponsor
MediciNova
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2013
Completion date
December 31, 2017
Enrollment
255 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, primary progressive, multiple sclerosis, secondary progressive